MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
Findings extend MiNK's iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1–4, 2026, in Banff, Alberta, Canada. The data, presented by Dr. Terese Hammond Head of Pulmonary and Inflammatory Diseases at MiNK Therapeutics and a Pulmonary and Critical Care physician , demonstrate a significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis (IPF), supporting a mechanistic role for iNKT insufficiency in advanced disease. “This work provides direct human tis
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaGlobeNewswire
- MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=INKT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=INKT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host DiseaseGlobeNewswire
- MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=INKT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
INKT
Earnings
- 11/14/25 - Beat
INKT
Sec Filings
- 1/14/26 - Form 4/A
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- INKT's page on the SEC website